deltatrials
Completed PHASE3 NCT00002109

Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy

Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT/ddI or AZT/ddC) Anti-Retroviral Therapy

Sponsor: Immunobiology Research Institute

Conditions HIV Infections
Interventions Didanosine Stavudine Thymopentin Zalcitabine Zidovudine
Updated 6 times since 2017 Last updated: Jun 23, 2005

This PHASE3 trial investigates HIV Infections and is currently completed. Immunobiology Research Institute leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Immunobiology Research Institute
Data source: NIH AIDS Clinical Trials Information Service

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States, Atlanta, United States, Austin, United States, Brookline, United States, Chicago, United States, Cleveland, United States, Coral Gables, United States, Dallas, United States, Fort Lauderdale, United States, Greenwich, United States and 28 more location s